Stockscreener 앱 받기
23.05
0.16%
0.010
전일 마감가:
$23.06
열려 있는:
$23.87
하루 거래량:
620.43K
Relative Volume:
0.30
시가총액:
$17.01B
수익:
$956.00K
순이익/손실:
$-196.68M
주가수익비율:
-96.04
EPS:
-0.24
순현금흐름:
$-113.02M
1주 성능:
+8.08%
1개월 성능:
+4.51%
6개월 성능:
+73.14%
1년 성능:
+461.96%
1일 변동 폭
$22.88
$24.18
1주일 범위
$20.43
$24.18
52주 변동 폭
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
23.08 | 17.01B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.06 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.54 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.44 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.04 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.15 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Summit Therapeutics (SMMT) Expected to Announce Earnings on Tuesday - MarketBeat
Summit Therapeutics Earnings: Critical Q4 Financial Report & Strategic Roadmap Reveal Coming February 24 - StockTitan
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.8%Time to Sell? - MarketBeat
3 Stocks That Could Trounce the Market in 2025 - Yahoo Finance
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8%Here's What Happened - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6%Here's Why - MarketBeat
SG Americas Securities LLC Sells 19,587 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
When the Price of (SMMT) Talks, People Listen - Stock Traders Daily
abrdn plc Increases Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024 - Citeline News & Insights
Calamos Advisors LLC Has $425,000 Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
2 Stocks That Could Soar Again in 2025 - MSN
Why Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4%Should You Sell? - MarketBeat
The drug industry is having its own DeepSeek moment | Mint - Mint
The Drug Industry Is Having Its Own DeepSeek Moment - The Wall Street Journal
China Universal Asset Management Co. Ltd. Acquires 17,014 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Brokerages - MarketBeat
Five Pine Wealth Management Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (SMMT): Jim Cramer Calls It a ‘Very Big Spec’ - Insider Monkey
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' - Benzinga India
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - MSN
Griffin Asset Management Inc. Purchases 42,900 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Lightning Round: I don't want to sell Adobe down here, says Jim Cramer - MSN
(SMMT) Investment Report - Stock Traders Daily
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - The Motley Fool
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
4.37%
자본화:
|
볼륨(24시간):